Firm News
Wiggin and Dana Represents Client Affibody AB in License and Collaboration Agreement with ACELYRIN, INC.
Wiggin and Dana represented its client Affibody AB in its license and collaboration agreement with ACELYRIN, INC. to develop and commercialize Affibody’s product, izokibep, worldwide excluding several major Asian markets already granted to Affibody’s partner Inmagene Biopharmaceuticals Co. Ltd. Izokibep is a bispecific molecule targeting interleukin-17A (IL-17), for multiple auto-immune diseases. Under the terms of the agreement, Affibody received a $25 million upfront payment and is eligible to receive up to $280 million in additional regulatory and sales milestones, plus royalties on sales in the markets covered by this agreement. Additionally, Affibody retained commercialization rights in the Nordic countries. Partner Patti Melick and Associate Madeleine Tavcar are proud and grateful to have had the opportunity to contribute to the success of this transaction.
To read the official press release, please click here.
